Concepedia

Xinan Sheng

XS

Statistics

Publications

2

Citations

29

H-Index

2

Active since

2024

Affiliations

Tongji University(Current)

Shandong First Medical University

Peking University First Hospital

Shandong Tumor Hospital

Peking University Cancer Hospital

Xinan Sheng is an author at Tongji University specializing in oncology, neoadjuvant immunotherapy, and human epidermal growth factor receptor 2-targeted therapy.

Publications per year

2024–2025

2

Publications

2

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.

Xinan Sheng, Cuijian Zhang, Yongpeng Ji et al. · Journal of Clinical Oncology · 2025 · 17 citations

, , +17

Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.

Xinan Sheng, Kaiwei Yang, Yongpeng Ji et al. · Journal of Clinical Oncology · 2024 · 12 citations

, , +17

1–2 of 2